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ABSTRACT The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosis, a serious infectious
disease of humans and animals. Once considered an esoteric tropical disease confined to Southeast Asia and northern Australia,
research on B. pseudomallei has recently gained global prominence due to its classification as a potential bioterrorism agent by
countries such as the United States and also by increasing numbers of case reports from regions where it is not endemic. An envi-
ronmental bacterium typically found in soil and water, assessing the true global prevalence of melioidosis is challenged by the
fact that clinical symptoms associated with B. pseudomallei infection are extremely varied and may be confused with diverse
conditions such as lung cancer, tuberculosis, or Staphyloccocus aureus infection. These diagnostic challenges, coupled with lack
of awareness among clinicians, have likely contributed to underdiagnosis and the highmortality rate of melioidosis, as initial
treatment is often either inappropriate or delayed. Even after antibiotic treatment, relapses are frequent, and after resolution of
acute symptoms, chronic melioidosis can also occur, and the symptoms can persist for months to years. In a recent article, Price
et al. [mBio 4(4):e00388-13, 2013, doi:10.1128/mBio.00388-13] demonstrate how comparative genomic sequencing can reveal the
repertoire of genetic changes incurred by B. pseudomallei during chronic human infection. Their results have significant clinical
ramifications and highlight B. pseudomallei’s ability to survive in a wide range of potential niches within hosts, through the ac-
quisition of genetic adaptations that optimize fitness and resource utilization.
GENOMIC FLEXIBILITY AND VARIATION ACROSS
BURKHOLDERIA PSEUDOMALLEI STRAINS
Like many other bacterial pathogens, analysis of the Burkhold-eria pseudomallei genome has provided vital insights into its
key virulence mechanisms. The “reference” B. pseudomallei ge-
nome, a clinical isolate from Thailand (K96243), was reported by
the Sanger Centre almost 10 years ago (1). This landmark study
revealed that the B. pseudomallei genome is exceptionally large,
comprising two circular chromosomes and a genome size of
7.2 Mb (1), with5,600 protein-coding genes and an impressive
armamentarium of virulence genes, including multiple type III
and type VI secretion systems, toxins, adhesins, and capsular poly-
saccharide clusters. Functional studies following this initial report
have yielded many novel findings in B. pseudomallei biology, such
as the identification of new toxins (2), and mechanisms of antibi-
otic resistance (3).
Recently, a whole-genome comparison of 11 B. pseudomallei
strains from different geographic regions (Thailand, Singapore,
Vietnam, and Australia) was reported (4). This study demon-
strated the existence of a sizeable degree of variation in genome
sizes among B. pseudomallei strains from diverse geographic loca-
tions, confirming a high level of intraspecies genetic diversity
(Fig. 1). It has been proposed that genomic regions that are vari-
ably present across strains, formally referred to as the “accessory
genome,” may contain genes that specifically modify the ability of
individual B. pseudomallei strains to cause different clinical symp-
toms or biological phenotypes (5). Besides accessory elements,
microscale genetic variations in genes commonly present in mul-
tiple B. pseudomallei strains (the “core genome”) were also ob-
served. Interestingly, a subset of the latter genes exhibited signa-
tures of positive selection, suggesting that their functions are
adapting under evolutionary pressure. Examples of cellular pro-
cesses highlighted through this approach included genes related to
siderophore biosynthesis, iron metabolism, and cell adhesion.
These results suggest that in its natural reservoir (soil), B. pseu-
domallei is likely to be constantly exposed to a variety of selective
pressures that can modify its genome and improve its chances of
survival.
GENETIC VARIATION DURING CHRONIC MELIOIDOSIS
Besides the comparison of geographically distinct isolates, another
important area of B. pseudomallei research lies in investigating
patterns of genetic variation between closely relatedB. pseudomal-
lei strains during different phases of human infection, for example
during chronic infection, as in the current study. Clinical evidence
suggests that chronic melioidosis may represent a distinct clinical
entity separate from acute melioidosis. Compared to acute B.
pseudomallei infections, which are commonly associated with
clinical risk factors such as diabetes, hazardous alcohol use, and
renal disease (6), chronic B. pseudomallei infections are consid-
ered less severe but are more localized in site and difficult to erad-
icate (7, 8). Such observations are consistent with a model where
B. pseudomallei strains causing chronic infection may have in-
curred additional genetic changes distinct from acute strains, al-
lowing the bacteria to adapt within the infected host. Until re-
cently, relatively few comprehensive genomic studies have
focused on chronic melioidosis. The recent study by Price et al. (9)
provides more-detailed insight of within-host evolution during a
chronic infection period of 10 years. Consecutive isolates were
collected and sequenced using next-generation technologies at
three different time points from a single patient with a pulmonary
infection. The first and third isolates (from sputum samples) were
139 months apart, with an intervening lung biopsy specimen iso-
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late at 37 months from the initial infection. During this period, the
patient was managed on intensive (ceftazidime and imipenem)
and maintenance (doxycycline and amoxicillin-clavulanic acid
[Augmentin]) antibacterial regimens. A genomic-scale compara-
tive analysis across the three isolates revealed two findings—first,
a signature of macrolevel genome reduction, and second, several
microlevel genetic changes. Regarding the first finding (mac-
roscale genome reduction), the investigators identified a pattern
of reductive evolution within human hosts, involving loss of gene
loci involved in specialized functions, such as facilitating bacterial
response to various environmental conditions. Among the
chronic isolates, four large genomic deletions were identified onB.
pseudomallei chromosome II (Fig. 2) which has been shown to
exhibit a chromosome-wide enrichment in genes related to acces-
sory functions and niche-specific adaptations (9). This phenom-
enon of genome reduction has also been observed in other bacte-
rial pathogens exhibiting a chronic disease phase. For example,
large-scale genomic deletions are also characteristic of chronic
Pseudomonas aeruginosa infection (10). Closer to home, the ge-
nome reductions observed in the B. pseudomallei chronic strains
also show a striking parallel to Burkholderia mallei, a separate
Burkholderia species originally derived from B. pseudomallei (11).
Tellingly, both the B. pseudomallei chronic strains and B. mallei
demonstrated genomic reduction across the same regions, such as
the genes BPSS1096 to BPSS1112 and BPSS1123 to BPSS1203,
which contain gene clusters related to secondary metabolism.
Because only 1 patient was studied, it remains to be seen if the
specific genome reduction events observed in this series are sto-
chastic or will be repeatedly observed in other cases of chronic
melioidosis.
Besides macroscale genome reductions, the chronic melioido-
sis strains also exhibited several microscale genetic alterations, in-
cluding insertions, deletions, and mutations. Genomic loci af-
fected by indels were often directly or indirectly associated with
pathogenesis, some examples being the virG gene of type VI secre-
tion system I, the multidrug efflux lipoprotein AmrA, and various
lipopolysaccharide (LPS) biosynthesis genes. Similarly, the
chronic melioidosis strains exhibited a series of nonsynonymous
single-nucleotide polymorphisms (SNPs) in genes related to ad-
aptation such as primary sigma factor (rpoD), beta-lactam resis-
tance (penA), and stress response (rpoS). Interestingly, while these
findings collectively hint at a nonstochastic nature of B. pseu-
domallei evolution during chronic infection, it should be ac-
knowledged that at present, the specific selective pressures in the
host that might have induced such genomic changes remain un-
clear. One obvious selective pressure might come from attack by
the host’s immune system. Candidate modulators of host immu-
nity in melioidosis might include the TNF-, IFN-, and TLR4
genes, as genetic knockouts ofTNF- and IFN- have been shown
to increase B. pseudomallei susceptibility in mouse models (12),
and genetic variation in Toll-like receptors (TLRs), in particular
TLR4 have been associated with host susceptibility to disease (13).
However, the impact of these innate immunity pathways on the
direct induction of genomic changes inB. pseudomallei remains to
be experimentally demonstrated. Other plausible processes driv-
ing genomic changes in B. pseudomallei during infection might
include differences in the host nutritional environment and the
impact of antibiotic therapy.
The findings of Price et al. (9) demonstrate thatB. pseudomallei
can indeed acquire genetic alterations during human infection,
and this general finding is also supported by independent studies
examining B. pseudomallei evolution under other clinical scenar-
FIG 1 Genome size distributions of B. pseudomallei (Bp) strains across dif-
ferent geographic regions: Thailand (blue), Singapore (red), Vietnam (or-
ange), and Australia (green).
FIG 2 Macroscale genome reduction in a chronic melioidosis patient. The figure shows B. pseudomallei chromosome II from strains K96243 (reference),
MSHR1043, and MSHR1655 (isolated 37 months later). The 3 B. pseudomallei isolates are depicted as a series of ordered locally collinear blocks (LCBs). The
vertical lines connect homologous LCBs across the isolates. Conserved segments across all the three isolates are colored pink, while portions colored green are
segments conserved across K96243 and MSHR1043. Segments conserved among MSHR1043 and MSHR1655 are colored brown. In strain MSHR1655, three
genomic segments (marked S1, S2, and S3) found in strain MSHR1043 have undergone deletion. Sequence alignments and ordering was performed using Mauve
2.3.1 (18).
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ios, including primary or relapsed melioidosis, or strains isolated
from different body sites of the same patient. Comparisons of
paired B. pseudomallei strains isolated during acute and relapsed
disease have been reported (4, 14). In these studies, only a handful
of genetic variations between acute and relapsed strains were iden-
tified. However, these genetic variations were biased toward
protein-coding genes with more than 50% of the variations being
nonsynonymous, suggesting the presence of active functional se-
lection within the human host. For example, relapsed strains were
associated with independent nonsynonymous mutations within
the same B. pseudomallei gene BPSS1483 (tetR, a transcriptional
regulator), that was not present in the original infecting strain
(14). Another study demonstrating B. pseudomallei’s ability to
evolve within a human host was reported by Price et al. (15), who
analyzed four patients diagnosed with acute disseminated me-
lioidosis. A comparison of B. pseudomallei strains isolated from
different tissue sites revealed considerable variation in the
genome-wide distribution of variable tandem repeats, although it
remains to be established if such variation represents neutral evo-
lution or active selection. Taken collectively, these studies demon-
strate B. pseudomallei’s remarkable ability to evolve genetically
even within the same human host.
FUTURE PERSPECTIVES
Chronic melioidosis accounts for 8 to 12% of melioidosis cases in
Thailand and Australia (6), with areas where melioidosis is not
endemic (Europe and North America) contributing to the re-
mainder (16, 17). There has been a paucity of published trials on
antimicrobial treatment of chronic melioidosis, and it remains
unclear whether treatment recommendations for this condition
remain the same as for acute melioidosis (6). Studies such as those
reported by Price et al. (9) are thus invaluable in providing evi-
dence that chronic melioidosis is indeed different from its acute
phase and highlighting potential avenues for chronic melioidosis
treatment. More generally, the sequencing technologies applied
here could also rapidly lead to powerful diagnostic tools for clin-
ical use, including both early detection and effective treatment.
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